» Articles » PMID: 23450201

The Nature of Activatory and Tolerogenic Dendritic Cell-derived Signal II

Overview
Journal Front Immunol
Date 2013 Mar 2
PMID 23450201
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Dendritic cells (DCs) are central in maintaining the intricate balance between immunity and tolerance by orchestrating adaptive immune responses. Being the most potent antigen presenting cells, DCs are capable of educating naïve T cells into a wide variety of effector cells ranging from immunogenic CD4(+) T helper cells and cytotoxic CD8(+) T cells to tolerogenic regulatory T cells. This education is based on three fundamental signals. Signal I, which is mediated by antigen/major histocompatibility complexes binding to antigen-specific T cell receptors, guarantees antigen specificity. The co-stimulatory signal II, mediated by B7 family molecules, is crucial for the expansion of the antigen-specific T cells. The final step is T cell polarization by signal III, which is conveyed by DC-derived cytokines and determines the effector functions of the emerging T cell. Although co-stimulation is widely recognized to result from the engagement of T cell-derived CD28 with DC-expressed B7 molecules (CD80/CD86), other co-stimulatory pathways have been identified. These pathways can be divided into two groups based on their impact on primed T cells. Whereas pathways delivering activatory signals to T cells are termed co-stimulatory pathways, pathways delivering tolerogenic signals to T cells are termed co-inhibitory pathways. In this review, we discuss how the nature of DC-derived signal II determines the quality of ensuing T cell responses and eventually promoting either immunity or tolerance. A thorough understanding of this process is instrumental in determining the underlying mechanism of disorders demonstrating distorted immunity/tolerance balance, and would help innovating new therapeutic approaches for such disorders.

Citing Articles

Factor of time in dendritic cell (DC) maturation: short-term activation of DCs significantly improves type 1 cytokine production and T cell responses.

Pozenel P, Zajc K, Svajger U J Transl Med. 2024; 22(1):541.

PMID: 38845003 PMC: 11155046. DOI: 10.1186/s12967-024-05368-4.


Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.

Ma Y, Shi R, Li F, Chang H Cell Commun Signal. 2024; 22(1):262.

PMID: 38715122 PMC: 11075321. DOI: 10.1186/s12964-024-01641-7.


IL-10-Engineered Dendritic Cells Modulate Allogeneic CD8 T Cell Responses.

Fortunato M, Amodio G, Gregori S Int J Mol Sci. 2023; 24(11).

PMID: 37298076 PMC: 10252493. DOI: 10.3390/ijms24119128.


Metabolic regulation of dendritic cell activation and immune function during inflammation.

Wu L, Yan Z, Jiang Y, Chen Y, Du J, Guo L Front Immunol. 2023; 14:1140749.

PMID: 36969180 PMC: 10030510. DOI: 10.3389/fimmu.2023.1140749.


A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.

Chen C, Weng T, Huang H, Huang L, Huang K, Chen P J Exp Clin Cancer Res. 2023; 42(1):29.

PMID: 36691089 PMC: 9869520. DOI: 10.1186/s13046-023-02601-8.


References
1.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

2.
Zitvogel L, Kroemer G . Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012; 1(8):1223-1225. PMC: 3518493. DOI: 10.4161/onci.21335. View

3.
Schulz O, Edwards A, Schito M, Aliberti J, Manickasingham S, Sher A . CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 2000; 13(4):453-62. DOI: 10.1016/s1074-7613(00)00045-5. View

4.
Zhu G, Augustine M, Azuma T, Luo L, Yao S, Anand S . B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood. 2008; 113(8):1759-67. PMC: 2647680. DOI: 10.1182/blood-2008-01-133223. View

5.
Cai G, Anumanthan A, Brown J, Greenfield E, Zhu B, Freeman G . CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008; 9(2):176-85. DOI: 10.1038/ni1554. View